[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Friday, 5 May 2006, 07:01 GMT 08:01 UK
Profit boost for French drugmaker
Sanofi-Aventis scientist at work
Sanofi-Aventis is the world's third-largest drugs firm
French drugs giant Sanofi-Aventis has seen its profits jump by almost 54%, lifted by the sale of rights to larger US rival Pfizer.

The firm said net profits, adjusted for Sanofi's merger with Aventis in 2004, were 2.2bn euros ($2.4bn; 1.5bn) in the first three months of the year.

Sanofi-Aventis said Pfizer's purchase of the rights to its Exubera inhaled insulin product had boosted earnings.

Excluding such one-off gains, the French firm's net profits rose by 20%.

Sanofi-Aventis, which is the world's third-largest pharmaceutical company, said underlying sales during the first quarter rose by 4.9%.

That came despite US patent protection for some of the company's most successful drugs, including arthritis treatment Arava and diabetes drug Amaryl, expiring in the final three months for 2005.

In March this year, Sanofi-Aventis announced it had bought a 25% stake in Czech generic drugmaker Zentiva for 430m euros.


SEE ALSO:
French drugs giant in Czech move
27 Mar 06 |  Business
Aventis and Sanofi set for merger
26 Apr 04 |  Business
Aventis formally rejects Sanofi
17 Feb 04 |  Business
Aventis profits lead bid defence
05 Feb 04 |  Business
Bid to create French drug giant
26 Jan 04 |  Business


RELATED INTERNET LINKS:
The BBC is not responsible for the content of external internet sites


PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific